Safety, Tolerability, and Efficacy of Generic Dolutegravir-containing Antiretroviral Therapy Regimens Among South Indian Human Immunodeficiency Virus-infected Patients.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 30192925.
- Also identified by DOI 10.1093/cid/ciy763 and PMC identifier 7182123.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In this first study of generic dolutegravir (DTG)-containing regimens in a low-resource setting, we assessed safety, tolerability, and efficacy within a prospective cohort of 564 patients with at least 6 months of clinical follow-up. We provide support for a large-scale transition to DTG as part of first-line regimens.
Medical subject headings
- HIV Infections
- HIV Integrase Inhibitors
- HIV-1
- Heterocyclic Compounds, 3-Ring